'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.

Br J Cancer · 2007 · PMC2360265 · PMID 18000506

Europe PMC DOI

hedged sentence

0.7860

closest p · 15.7× alpha

0.7860

boldest claim

The sentences

failed to reach statistical significanceP =0.786not close (p > 0.1)

Although patients with DEL19 mutation had numerically higher TTP, when compared with L858R mutation patients, this difference failed to reach statistical significance (80 vs 64 weeks, P =0.786).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.